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EFFECTS OF A SOFT THUMB BASE SPLINT IN PERSONS WITH
CARPOMETACARPAL OSTEOARTHRITIS: A RANDOMISED CONTROLLED
TRIAL
M. Hermann, T. Nilsen, C.S. Eriksen, B.S. Christensen, I.-K. Haugen, I.
Kjeken. Diakonhjemmet Hosp., Oslo, Norway
Purpose: To assess the effectiveness, regarding pain, hand strength,
function in daily activities of a prefabricated soft splint for persons with
osteoarthritis of the CMC1-joint.
Methods: In this randomised controlled trial, 59 persons with CMC1-OA
were included. The control-group (n¼29) received hand exercises and the
splint-group (n¼30) received hand exercises and splint. The following
assessmentswereperformed atbaseline andafter 2months:Grip- andpinch
strength in Newton (N) were measured with Grippit. Pain during resisted
gripwasmeasuredonanumeric rating scale (NRS) (0¼nopain). Thumbweb-
space was measured with Gripsize and joint mobility was recorded in mil-
limetre (mm).Self-reportedhand functionwasassessedwithAUSCANonﬁve
point Likert scales (0¼no problem). Patients were recommended to perform
hand exercises twice a day and the splint-groupwere instructed towear the
splint when having pain and/or when performing heavier manual tasks. At
twomonthswe alsomeasured grip strength and pain bothwith andwithout
splint in the splint-group and conducted a semi-structured interview were
we asked splint-group about their experience with the splint.
Results: The mean age of the participants was 70.5 years (SD 6.7), mean
disease duration was 15.2 years, and one third had CMC-OA grade 3 or
more. Nine participants were provided with a splint for their right thumb,
4 for left thumb and 17 participants for both thumbs. There were no
signiﬁcant differences between the groups in any outcome after two
months. In the splint-group, pain during resisted grip was signiﬁcant less
when wearing the splint compared to without. Most participants were
satisﬁed with the splint and reported the splint as useful, especially during
household management.
Conclusions: The results indicate that a soft prefabricated splint has an
immediate pain- relieving when worn, but no long term effect in terms of
reduced inﬂammation and pain, or improved strength or activity perfor-
mance in patients with CMC1-OA.
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EFFICACY AND SAFETY OF GINGER IN OSTEOARTHRITIS PATIENTS:
A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS
V.N. Folmer 1, E.M. Bartels 1, H. Bliddal 1, R.D. Altman 2, C. Juhl 3, W.
Zhang 4, R. Christensen 1,3. 1Musculoskeletal Statistics Unit, The Parker
Inst., Copenhagen Univ. Hosp., Frederiksberg, Copenhagen, Denmark;
2David Geffen Sch. of Med., Univ. of California, Los Angeles, CA, USA; 3 Inst.
of Sports Sci. and Clinical Biomechanics, Univ. of Southern Denmark,
Odense, Denmark; 4Academic Rheumatology, Univ. of Nottingham, Clinical
Sci. Building, City Hosp., Nottingham, United Kingdom
Purpose: To assess the clinical efﬁcacy and safety of ginger for symp-
tomatic treatment of osteoarthritis (OA), using meta-analysis of all pub-
lished randomized placebo-controlled trials (RCTs).
Methods: A systematic search of the bibliographic databases Medline,
Embase, Cinahl and Sciﬁnder, as well as The Cochrane Central Register of
Controlled Trials was carried out, identifying RCTs comparing any oral
ginger treatment with placebo in OA patients. Major outcomes for efﬁcacy
were reduction in pain and disability, and harmwas assessed generically as
the number of withdrawals due to adverse events. Efﬁcacy effect size (ES)
was estimated using Hedges's standardized mean difference with negative
values being in favor of ginger. Safety effect size was estimated by the risk
ratio (RR) with RR values above 1 indicating potential harm/discomfort
with ginger. Standard random-effects meta-analysis was used as default
option, whereas the ﬁxed-effect model was applied for sensitivity anal-
yses. Inconsistency was evaluated by the I-squared index (I2). All effect
sizes were reported with 95% conﬁdence intervals (95% CIs).
Results: Out of 76 retrieved references, 34 abstracts were scrutinized
according to the eligibility criteria. Five placebo-controlled trials (593
patients) contributed to the meta-analysis on pain, where the majority of
studies applied an inappropriate intention-to-treat (ITT) population in theanalyses. Pain reduction, following the use of ginger, revealed a small degree
of heterogeneity among the trials (I2 ¼ 27%), with a statistically signiﬁcant
ES of -0.30 (95% CI: -0.50, -0.09, P ¼ 0.005), in favor of ginger. In terms of
reduction in disability, gingerwas also signiﬁcantly better than placebo ES¼
-0.22 (95% CI: -0.39, -0.04; P ¼ 0.01; I2 ¼ 0%). Patients given ginger were
more than twice as likely to discontinue treatment due to adverse events as
were those given placebo (RR¼ 2.33 [95% CI: 1.04, 5.22]; P ¼ 0.04; I2 ¼ 0%).
Conclusions: Based on the small number of trials and inappropriate/
unclear use of ITT analyses, our overall conﬁdence in the estimates corre-
sponds to moderate quality evidence. Ginger treatment seems efﬁcacious
and reasonably safe in OA patients, realizing that further research could
have an impact on our conﬁdence in this herbal remedy. Further studies are
required to conﬁrm the efﬁcacy of this therapy. Considering the balance
between desirable and undesirable effects, use of ginger therapy may be
a therapeutic option for the OA patient with an interest in herbal remedies,
where after a few months treatment, the effect should be evaluated.
Acknowledgements: This study was supported by grants from The Oak
Foundation.
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DESIGNG AND TESTING A WEB-BASED PHYSICAL ACTIVITY
INTERVENTION FOR PATIENTS WITH OSTEOARTHRITIS IN HIP AND/OR
KNEE
D. Bossen. Nivel Inst., Utrecht, Netherlands
Purpose: Due to elevated fear of pain, catastrophizing thoughts and joint
stiffness, a large group of patients with hip and/or knee osteoarthritis (OA)
remain sedentary. Although inactivity may enhance in short-term pain
reduction, prolonged inactivity may augment functional decline. There-
fore, we developed a web-based intervention that provides a highly
individualized behaviorally based physical activity (PA) program. The aim
of this study is to describe the development, preliminary effectiveness and
usability of a 9 week website intervention on PA behavior change in
individuals with hip and/or knee OA.
Methods:We used an iterative designmethodology for the creation of aweb-
based intervention. The intervention incorporates core principles of the
behaviour graded activity theory. A pilot study prototype was tested trough
a non-randomized pilot study among 20 patients with OA. PA levels and pain
scores were measured trough online questionnaires (week 0, 6 and 12).
Subsequently, a heuristic evaluation and a thinking aloud approach were
performed to determine the usability of the intervention. Information about
usersatisfactionwascollected throughsemistructured face-to-face interviews.
Results:After several iterations of testing and revising, we developed
a ﬁnal version of the web-based intervention.The PA program includes an
introduction module and 8 text based week assignments. Twenty OA
patients, between 50 and 80 years of age, participated in the pilot study
and received the intervention. After 12 weeks, there was a non-signiﬁcant
increase in PA (1697 to 2044 minutes per week).After six weeks, pain
scores increased from 5.3 to 6.6 (p¼0.04). After 12 weeks, however, this
signiﬁcant difference disappeared. Although usability tests revealed some
usability issues, participants considered the intervention as helpful. In
particular, users were enthusiastic to perform physical exercises in their
own time and at their own pace.
Conclusions: This paper outlines the development and usability of a web-
based PA intervention for patients with hip and/or knee OA. The preliminary
results from the pilot study suggests that the intervention is promising in
the promotion of PA, even though effects were not statistical signiﬁcant.
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CHONDROITIN SULFATE AND NOT ACETAMINOPHEN EFFECTIVELY
REDUCES SYNOVITIS IN PATIENTS WITH KNEE OSTEOARTHRITIS:
RESULTS FROM A PILOT STUDY
J. Monfort 1, C. Orellana 2, F. Montañés 1, N. Garcia 3, L. Tio 3, P.
Benito 1. 1Hosp. del Mar of Barcelona, Barcelona, Spain; 2Corporació
Sanitària Parc Taulí, Sabadell, Spain; 3 IMIM, Inst. Municipal de
Investigacions Mèdiques, Barcelona, Spain
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S284Purpose: Inﬂammation of synovial membrane in osteoarthritis (OA) is one
of the major signs of structure damage during disease progression.
Chondroitin sulfate (CS) is effective in the treatment of OA. Recently, CS has
shown to reduce joint swelling and effusion in OA patients in the NIH-
funded GAIT study (N Engl J Med 2006,23;354(8):795-808). The purpose of
this pilot study was to compare the effect of CS (Condrosan,Bioibérica
S.A.,Barcelona) on synovitis of OA patients vs. acetaminophen.
Methods: Synovitis (synovial hypertrophy+effusion4mm) was evaluated
by sonography in 45 patients treated with CS (800mg/day) or acetamin-
ophen (4g/day) for 6 months. Patients were followed-up until month 9 to
evaluate the carry-over effect. Synovial hypertrophy was assessed by
sonography and synovial effusion was quantiﬁed by artrhocentesis.
Symptomatic effect of both treatments was also evaluated by Lequesne
Algofunctional Index (baseline,1.5,3,6 and 9 months). Analysis of contin-
uous variables was based on analyses of covariance (ANCOVA) model.
Comparison between the two groups was obtained using an independent
sample t-test for quantitative variables or a chi-squared test for qualitative
variables. P values less than or equal to 0.05 were considered statistically
signiﬁcant for each variable.
Results: Eligible patients had clinical and radiographic evidence of OA
(Kellgren&Lawrence grade 2 and 3) with synovitis assessed by sonography.
Mean age of patients was 70.44 years. 72.09% were women. Mean BMI was
28.97. At the end of the study, CS signiﬁcantly reduced synovitis compared
to acetaminophen (p<0.01). Compared to baseline, CS treated patients
presented a 25.45% reduction of synovitis (6.641.69 vs.
4.881.69;p<0.05) and, speciﬁcally, a 61.93% reduction of synovial
hypertrophy (3.731.96 vs. 2.311.98;p<0.05). No effect on synovitis was
observed in the acetaminophen group over time. Additionaly, CS and not
acetaminophen effectively reduced functional incapacity after 6 months of
treatment (CS group: 11.52.5 vs. 7.883; p<0.01. Acetaminophen group:
9.94.1 vs. 8.34.9; n.s.). CS functional improvement remained signiﬁcant
at month 9 after treatment supression conﬁrming the carry-over effect of
CS.
Conclusions: These results suggest that CS effectively reduces synovitis
and clinical symptoms of OA, though these effects are not observed with
acetaminophen. It also conﬁrms the results from the NIH-funded GAIT
study. Therefore, CS seems to be a more effective therapeutic tool than
analgesics for patients with OA and synovial inﬂammation. Its carry over
effect (also conﬁrmed in this study) and its well-recognized safety proﬁle,
provide additional clinical beneﬁts vs. acetaminophen.
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CLINICAL EFFICACY OF ALENDRONATE TREATMENT IN PATIENTS WITH
HIP OSTEOARTHRITIS: A 2-YEAR RANDOMIZED CONTROLLED TRIAL
T. Nishii, S. Tamura, T. Shiomi, T. Sakai, M. Takao, H. Yoshikawa,
N. Sugano. Osaka Univ. Med. Sch., Osaka, Japan
Purpose: Degeneration and loss of cartilage is the main pathogenesis of
hip and knee osteoarthritis, but periarticular bone alteration such as
subchondral bone changes and osteophyte formation also plays an
important role on disease progression and clinical symptom. Regulation of
those bone turnovers by antiresorptive drugs may be effective approach
for osteoarthritis treatment. Clinical trials of bisphosphonate treatments
have not been conducted in hip osteoarthritis. Our objectives were to
examine clinical efﬁcacy of alendronate treatment in hip osteoarthritis by
a 2-year randomized controlled study.
Methods: We prospectively enrolled 51patients with symptomatic hip
osteoarthritis who met the following criteria; the Kellgren-Lawrence (KL)
osteoarthritis grade of 2 or more on anteroposterior radiographs, age
between 30 and 90 years, and no history of bisphosphonate administra-
tion. All participants provided informed consent to the study which was
approved by the Institutional Review Board. The patients were randomly
assigned to either the alendronate group (alendronate 35mg/week and
calcium lactate 600mg/day) or the control group (calcium lactate 600mg/
day) for 2 years in 1:2 ratios. All patients were scheduled to receive the
following assessments; (1) WOMAC pain score and visual analogue score
(VAS) at 6-month intervals, (2) anteroposterior pelvic radiographs at 6-
month intervals, (3) biochemical markers of urinary NTX-I and CTX-II at 0,
6,12,24months, (4) DEXA of the hip at 0, 6,12,24months, and (5) MRI of the
hip at 0, 12 months. Between the alendronate and control groups, changesof the pain scores, NTX-I and CTX-II values, bone mineral density were
compared using Mann-Whitney test. Osteoarthritis progression and
change of bone marrow edema (BME) on MRI were compared using
Fisher's exact test. Osteoarthritis progression was deﬁned as worsening of
joint space narrowing on radiographs or conversion to total hip arthro-
plasty. If the patient had osteoarthritis in both hips, only one hip withmore
severe osteoarthritis was included.
Results: Thirty-three patients in the alendronate group and 18 patients in
the control group were enrolled. During the follow-up, 8 patients were
excluded due to abdominal discomfort and transfer of the residence, and
remaining 30 patients in the alendronate group and 13 patients in the
control group were analyzed. At the entry, there were no signiﬁcant
differences of age, gender, BMI, KL grades, VAS, urinary NTX-I and CTX-II
values between the two groups. At 24 months, VAS pain reduction was
signiﬁcantly better in the alendronate group (p<0.05). Radiographic
osteoarthritis progression was seen in 14 hips (47%) of the alendronate
group and in 5 hips (38%) in the control group, without signiﬁcant
difference. NTX-I values were signiﬁcantly lower at all times, and CTX-II
values were signiﬁcantly lower at 24 months in the alendronate group (Fig
1). Among each group, however, therewas no signiﬁcant difference of CTX-
II values between the hips with and without osteoarthritis progression. On
MRI, the alendronate group showed higher frequency of BME reduction at
12 moths (31%), as compared with 0% in the control group.
Conclusions: Alendronate treatment had clinical efﬁcacy of pain reduction
but failed to show preventing effect of hip osteoarthritis progression.
These ﬁndings were in accordance with previous clinical trials of
bisphosphonate treatment in knee osteoarthritis. In knee osteoarthritis,
early reduction of CTX-II by bisphosphonate treatment was assumed
a prognostic index for prevention of osteoarthritis progression, however,
those associations were not found in hip osteoarthritis. Further investi-
gations regarding development of potent surrogates for disease progres-
sion and detection of optimal responders of bisphosphonate treatments
are required.
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SAFETY AND EFFICACY PROFILE OF NANO-FORMULATED, LOWER DOSE
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
V. Strand 1, R. Altman 2, S. Daniels 3, G. Manvelian 4. 1 Stanford Univ., Palo
Alto, CA, USA; 2UCLA Med. Ctr. RHU, Los Angeles, CA, USA; 3 Premier Res.
Group Limited, Clin. Res. Ctrs., Austin, TX, USA; 4 Iroko Pharmaceuticals,
Philadelphia, PA, USA
Purpose: NSAIDs are routinely prescribed for musculoskeletal conditions
including arthritis. Safety and tolerability, a common concernwith NSAIDs,
have shown to be dose-dependent. We present the safety and efﬁcacy of
investigational, nano-formulated, lower dose, oral NSAIDs (diclofenac,
indomethacin, and naproxen) in an established acute pain model.
Methods: All 3 Phase 2 trials were multi-center, randomized, double-
blind, single-dose, parallel-group, active- and placebo-controlled studies.
More than 200 subjects (N¼202 [diclofenac], N¼203 [indomethacin], and
N¼253 [naproxen]) were enrolled for each trial. Subjects were 18-50 years
of age, had extraction of 2 third molars (1 had to be a fully or partially
